EUFLEXXA®

About EUFLEXXA® — Non-Avian Sodium Hyaluronate for Knee Osteoarthritis

EUFLEXXA® is an intra-articular hyaluronic acid viscosupplement formulated as 1% sodium hyaluronate — its generic name — in phosphate-buffered saline. FDA device labeling describes it as a sterile, highly purified, high-molecular-weight hyaluronan extracted from bacterial cells, with a molecular weight range of 2.4 to 3.6 million daltons. Hyaluronan is naturally present in synovial fluid, where it contributes to joint lubrication and shock absorption; in osteoarthritis, its concentration and quality in the knee joint may be reduced. Viscosupplementation with EUFLEXXA® supplements the joint environment, helping to restore the low-molecular-weight forms of hyaluronan that are depleted in the osteoarthritic knee. [2]

The non-avian source is the defining clinical differentiator. Most competing viscosupplements are derived from avian material, while EUFLEXXA® is produced through bacterial fermentation. This process eliminates the avian protein allergy considerations associated with avian-derived products. This makes EUFLEXXA® a relevant option for practices managing patients with sensitivities to avian proteins, feathers, or eggs, as well as for clinicians who prefer non-animal-derived HA products more broadly. [2][5]

Moreover, EUFLEXXA® is not a corticosteroid. It is a sodium hyaluronate medical device that works through a viscosupplementation mechanism entirely distinct from the anti-inflammatory pathway of steroid injections, which is a practical distinction when counseling patients comparing hyaluronic acid viscosupplementation with corticosteroid or other intra-articular treatment options. [2]

EUFLEXXA® Product Spotlight

Each EUFLEXXA® 20 mg/2 mL prefilled syringe contains 2 mL of sterile 1% sodium hyaluronate solution, delivering 20 mg per injection. The standard EUFLEXXA® dosage is 2 mL injected intra-articularly into the affected knee once weekly for 3 weeks, completing a full 3-injection course. The syringe is intended for single use by a qualified healthcare professional and should not be used if the blister packaging is opened or damaged. [2]

For clinics evaluating procurement, EUFLEXXA® presents a straightforward inventory profile: one core SKU, a familiar 3-injection weekly schedule, and an established HCPCS billing pathway. Wholesale pricing, course cost, and documentation requirements vary by market and account status — practitioners can buy orthopedic injections through Doctor Medica’s broader catalogue to compare EUFLEXXA® alongside other viscosupplementation and joint-support products available for licensed professional procurement. [2]

Treatment Areas and Patient Indications

In clinical practice, ideal candidates include patients with persistent knee OA pain who meet the following criteria:

• Inadequate Conservative Relief: Insufficient pain management from structured exercise, physical therapy, or oral analgesics.
• Appropriate for Non-Surgical Care: Patients seeking a non-surgical intervention to manage progressive symptoms.
• Avian Protein Sensitivity: A key subpopulation where EUFLEXXA®’s biofermentation source makes it the preferred alternative over avian-derived viscosupplements for patients with known sensitivities to eggs, feathers, or poultry.

Clinical Scope: EUFLEXXA® is indicated only for the knee joint and must be administered exclusively by a qualified healthcare professional. It is not a patient self-injection product, and marketing materials must not present it as a cure for osteoarthritis or as a cartilage regeneration treatment.

Absolute Contraindications

Do not administer EUFLEXXA® to patients presenting with:

• Known hypersensitivity to hyaluronan preparations.
• An active knee joint infection.
• Active skin disease or localized infection at the targeted injection site.

Technical Administration Warnings

• Intravascular Injection: Do not inject EUFLEXXA® intravascularly.
• Chemical Incompatibility: Do not administer EUFLEXXA® through a needle previously exposed to solutions containing benzalkonium chloride. Quaternary ammonium salts cause immediate precipitation when mixed with hyaluronan solutions.

Administration — Injection Protocol and Timeline

EUFLEXXA® follows a straightforward clinical protocol, administered as a series of three 2 mL intra-articular injections given weekly over three consecutive weeks. [2]

Step-by-Step Administration

• Preparation: Before administering each injection, the practitioner must remove any joint swelling or effusion from the target knee. [2]
• Injection: Deliver the full 2 mL contents of the prefilled syringe into the joint space using strict aseptic technique. [2]
• Post-Injection Care: Advise patients to avoid strenuous activity or prolonged weight-bearing (such as jogging, tennis, heavy lifting, or standing for more than one hour at a time) for 48 hours post-procedure. [2]

Clinical Efficacy and Onset Timeline

While individual symptom relief varies based on osteoarthritis (OA) severity and patient factors, clinical data demonstrates a progressive and lasting therapeutic window:

• Symptom Onset: Some patients notice initial improvement during the treatment course, while many experience progressive symptom relief over the several weeks following the final injection. [2]
• The FLEXX Trial Results: A double-blind, randomized, saline-controlled study evaluated efficacy through 26 weeks post-treatment. The trial demonstrated a highly statistically significant reduction in knee OA pain, with a 53% median reduction in the EUFLEXXA® group compared with 38% in the saline control group. [1] Improvements were also documented in joint function and overall treatment satisfaction. [1]

Clinical Note: Full therapeutic efficacy relies on treatment compliance; patients must complete the full 3-injection weekly course to optimize long-term clinical outcomes.

Why Practitioners Choose EUFLEXXA®

EUFLEXXA®’s non-avian, biofermentation-derived sodium hyaluronate eliminates concerns about avian protein allergy, broadening the eligible patient population compared with avian-derived HA products and offering a clinically distinct option for practices that encounter patients unable to use avian-sourced viscosupplements. [2][5]

Moreover, EUFLEXXA® uses a standard 3-injection weekly course with an established HCPCS J code (J7323) and a well-documented billing pathway through the intra-articular injection CPT codes. Manufacturer-linked copay assistance programs may also be available to eligible patients, helping reduce out-of-pocket costs and supporting treatment completion of the full 3-injection series. Clinic teams should verify current program terms, eligibility criteria, and payer restrictions before advising patients on any support program. [3][4]

EUFLEXXA® vs Competing Viscosupplements

EUFLEXXA® vs ORTHOVISC®

EUFLEXXA® and ORTHOVISC® are both non-avian hyaluronic acid viscosupplements, making the comparison especially relevant for practices that have already ruled out avian-derived products. EUFLEXXA® is administered as 3-weekly injections, while ORTHOVISC® is typically given as a 3- to 4-injection course, depending on labeling and payer requirements. The products also differ in their molecular weight profiles and formulation sources. Clinics that stock multiple non-avian HA options alongside EUFLEXXA® can buy ORTHOVISC® through Doctor Medica. [2]

EUFLEXXA® vs MONOVISC®

EUFLEXXA® is a 3-injection weekly course, while MONOVISC® is a single-injection viscosupplement — the most immediate practical difference for clinic scheduling and patient compliance. Both are non-avian HA products, but they differ in administration format, dose, and cross-linking profile. Practices evaluating single-injection versus multi-injection protocols within a non-avian HA formulary can buy MONOVISC® through Doctor Medica. [2]

EUFLEXXA® vs HYALGAN®

EUFLEXXA® is non-avian and biofermentation-derived, while HYALGAN® is an avian-derived sodium hyaluronate product. For patient-specific sourcing decisions where avian protein sensitivity is a factor, the distinction is clinically meaningful. HYALGAN® is typically administered as a 3- to 5-injection course, while EUFLEXXA® uses 3 weekly injections. Practices that maintain both avian and non-avian HA options for patient-specific selection can buy HYALGAN® through Doctor Medica. [2]

EUFLEXXA® vs SYNVISC®

EUFLEXXA® is a non-avian, non-cross-linked sodium hyaluronate product, while SYNVISC® is based on avian-derived, cross-linked hylan G-F 20. The two differ in source, molecular structure, and injection schedule–SYNVISC® is available in both a 3-injection format and Synvisc-One® as a single-injection option, while EUFLEXXA® follows a fixed 3-injection weekly course. For practices comparing avian and non-avian HA chemistry and scheduling flexibility, buy SYNVISC® is available through Doctor Medica. [2]

EUFLEXXA® vs SUPARTZ®

EUFLEXXA® is a non-avian biofermentation-derived sodium hyaluronate, while SUPARTZ® is an avian-derived sodium hyaluronate administered as a multi-injection weekly series. Both are sodium hyaluronate products, but the source distinction is the primary clinical differentiator — particularly relevant when screening patients for avian protein sensitivity. Clinics that carry both avian and non-avian sodium hyaluronate options can buy SUPARTZ® through Doctor Medica. [2]

Administration — Injection Protocol and Timeline

The safety profile of EUFLEXXA® is broadly consistent with the intra-articular hyaluronic acid (HA) viscosupplementation class, with local reactions typically resolving without specific intervention. [2]

Common Adverse Events

Device- and procedure-related adverse events documented in FDA labeling include:

• Device-Related Events: Arthralgia (joint pain), back pain, extremity pain, musculoskeletal pain, and joint swelling. [2]
• Procedure-Related Events: Injection-site pain, localized arthritis, transient joint swelling, and joint effusion. [2]

Clinical Monitoring

While transient local reactions are common to HA injections, patients should be monitored for persistent or worsening symptoms, fever, or any signs of local or systemic infection. As with any invasive joint procedure, serious adverse events like septic arthritis are possible. [2]

Long-Term Safety and Repeat Cycles

• Established Window: FDA labeling confirms that the safety of repeated EUFLEXXA® treatment cycles has been established for up to one year. [2]
• Immunogenicity: The potential for an immune response following repeated long-term exposure has not been fully assessed in humans. [2]
• Safety Extension Data: Clinical data, including the FLEXX trial safety extension, show no distinctive long-term safety signals or cumulative toxicities beyond typical, transient injection-related reactions. [1][2]

Regulatory Status, Billing, and Copay Assistance

EUFLEXXA® is an FDA-authorized intra-articular sodium hyaluronate viscosupplement for knee osteoarthritis pain, indicated for patients who have not responded adequately to conservative non-pharmacologic therapy and simple analgesics. It is classified as a medical device and is intended for administration by a qualified healthcare professional. [2]

For billing purposes, the EUFLEXXA® J code is HCPCS J7323, listed as a per-dose code for a 3-weekly-injection series at 20 mg once weekly per knee. The CPT code for the injection procedure is typically CPT 20610 for a major joint injection, or CPT 20611 when ultrasound guidance with permanent recording and reporting is performed. If aspiration and injection are performed in the same session, CMS guidance indicates that only one unit of CPT 20610 or 20611 should be billed. Practitioners should verify the current EUFLEXXA® J code, applicable CPT code, payer-specific rules, modifiers, and documentation requirements before submitting claims. [3]

EUFLEXXA® copay assistance and access support may be available through manufacturer-linked programs, including a Solution Center, a Patient Direct Program for underinsured or uninsured patients, and an EUFLEXXA® Commitment refund program. Eligibility, current terms, deadlines, and payer restrictions should be verified directly with the program before treatment planning. [4]

About the Manufacturer

EUFLEXXA® is associated with Ferring Pharmaceuticals in current US commercial materials, which provide product information, safety data, coverage resources, and patient support pathways. Ferring is an international biopharmaceutical company focused on specialty therapeutics; its US operations include the EUFLEXXA® product line in the orthopedic and musculoskeletal injectable category. Practitioners should verify the current manufacturer, distributor, and product identifier details on the product label before procurement, as these details may be updated. [2][5]

Doctor Medica supplies licensed practitioners with EUFLEXXA® and a broader range of orthopedic injectable products through verified channels. Clinics whose practices also cover aesthetic indications can buy dermal fillers or buy HA dermal fillers through Doctor Medica’s aesthetic injectable catalog separate from EUFLEXXA®’s orthopedic viscosupplementation role.

Doctor Medica has supplied verified orthopedic injectable products to licensed medical professionals since 2006, with competitive wholesale pricing, guaranteed authenticity, and verifiable LOT numbers. Licensed practitioners looking to buy EUFLEXXA® wholesale, order EUFLEXXA®, purchase EUFLEXXA®, or buy EUFLEXXA® injection online can browse the Doctor Medica catalogue or contact representatives for availability, lot documentation, and procurement support.

FAQs

What is EUFLEXXA®?

EUFLEXXA® is a non-avian sodium hyaluronate viscosupplement supplied as a 20 mg/2 mL prefilled syringe. It is administered as a 3-injection weekly course to relieve knee pain due to osteoarthritis in patients who have not responded adequately to conservative therapy or simple analgesics. [2]

What is EUFLEXXA® used for?

EUFLEXXA® is used for the relief of knee pain associated with osteoarthritis in patients who have not achieved adequate relief from non-pharmacologic therapy or simple analgesics such as acetaminophen. It is injected intra-articularly into the knee by a qualified healthcare professional. [2]

Is EUFLEXXA® a steroid?

No. EUFLEXXA® is sodium hyaluronate — a hyaluronic acid medical device used for viscosupplementation. It is not a corticosteroid and works through a fundamentally different mechanism from steroid injections. [2]

What is EUFLEXXA®’s generic name?

The generic name of EUFLEXXA® is sodium hyaluronate. It is produced via bacterial fermentation, making it a non-avian, biofermentation-derived HA product. [2]

How long does it take for EUFLEXXA® to work?

Response varies by patient. Some individuals may notice improvement during or shortly after completing the 3-injection series, while others are assessed over several weeks post-treatment. The FLEXX trial followed patients through 26 weeks, supporting evaluation of response over time rather than immediately after the first injection. [1]

What is the success rate of EUFLEXXA® injections?

In the FLEXX trial, EUFLEXXA® produced a statistically significant 53% median reduction in knee pain from baseline at 26 weeks, compared with 38% in the saline control group. Improvements in function and treatment satisfaction were also reported. Individual outcomes vary based on OA severity, patient characteristics, and treatment completion. [1]

What are the long-term side effects of EUFLEXXA®?

FDA labeling documents the safety of repeated treatment cycles through one year. Available data do not highlight a distinctive long-term safety signal beyond typical injection-related reactions, though the potential for immune response after repeated exposure has not been fully assessed. Possible adverse events include joint pain, swelling, effusion, and injection-site reactions. [2]

Is copay assistance available for EUFLEXXA®?

Manufacturer-linked support programs may be available, including a Solution Center, Patient Direct Program, and EUFLEXXA® Commitment refund program. Eligibility, current terms, and payer restrictions should be verified directly with the program before treatment planning. [4]

Where can practitioners buy EUFLEXXA® wholesale?

Licensed practitioners can buy EUFLEXXA® wholesale through Doctor Medica, which supplies orthopedic injectables with competitive wholesale pricing, verifiable LOT numbers, and representative support for product availability and procurement documentation.

Citations

1. Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension: the FLEXX trial. Seminars in Arthritis and Rheumatism. 2009;39(1):1–9. https://pubmed.ncbi.nlm.nih.gov/19539353/
2. S. Food and Drug Administration. EUFLEXXA® Prescribing Information / Device Labeling. FDA. https://www.accessdata.fda.gov/cdrh_docs/pdf/P010029S008c.pdf
3. Centers for Medicare & Medicaid Services. Billing and Coding: Intraarticular Knee Injections of Hyaluronan (A56157). CMS. Last Updated 06/25/2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56157
4. EUFLEXXA®. Coverage & Support. Ferring Pharmaceuticals. https://www.euflexxa.com/coverage-and-support/
5. EUFLEXXA®. About EUFLEXXA. Ferring Pharmaceuticals. https://www.euflexxa.com/about-euflexxa/

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.